Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciardiello, F.
Right arrow Articles by Tortora, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciardiello, F.
Right arrow Articles by Tortora, G.
Clinical Cancer Research Vol. 5, 909-916, April 1999
© 1999 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Antitumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C2251

Fortunato Ciardiello2, Roberto Bianco, Vincenzo Damiano, Sonya De Lorenzo, Stefano Pepe, Sabino De Placido, Zhen Fan, John Mendelsohn, A. Raffaele Bianco and Giampaolo Tortora

Cattedra di Oncologia Medica Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy [F. C., R. B., V. D., S. D. L., S. P., S. D. P., A. R. B., G. T.], and University of Texas M. D. Anderson Cancer Center, Houston, Texas [Z. F., J. M.]

Epidermal growth factor (EGF)-related proteins such as transforming growth factor {alpha} (TGF-{alpha}) control cancer cell growth through autocrine and paracrine pathways. Overexpression of TGF-{alpha} and/or its receptor (EGFR) has been associated with a more aggressive disease and a poor prognosis. The blockade of EGFR activation has been proposed as a target for anticancer therapy. Monoclonal antibody (MAb) C225 is an anti-EGFR humanized chimeric mouse MAb that is presently in Phase II clinical trials in cancer patients. Previous studies have suggested the potentiation of the antitumor activity of certain cytotoxic drugs, such as cisplatin and doxorubicin, in human cancer cell lines by treatment with anti-EGFR antibodies. We have evaluated in human ovarian, breast, and colon cancer cell lines, which express functional EGFR, the antiproliferative activity of MAb C225 in combination with topotecan, a cytotoxic drug that specifically inhibits topoisomerase I and that has shown antitumor activity in these malignancies. A dose-dependent supraadditive increase of growth inhibition in vitro was observed when cancer cells were treated with topotecan and MAb C225 in a sequential schedule. In this respect, the cooperativity quotient, defined as the ratio between the actual growth inhibition obtained by treatment with topotecan followed by MAb C225 and the sum of the growth inhibition achieved by each agent, ranged from 1.2 to 3, depending on drug concentration and cancer cell line. Treatment with MAb C225 also markedly enhanced apoptotic cell death induced by topotecan. For example, in GEO colon cancer cells, 5 nM topotecan, followed by 0.5 µg/ml MAb C225, induced apoptosis in 45% cells as compared with untreated cells (6%) or to 5 nM topotecan-treated cells (22%). Treatment of mice bearing established human GEO colon cancer xenografts with topotecan or with MAb C225 determined a transient inhibition of tumor growth because GEO tumors resumed the growth rate of untreated tumors at the end of the treatment period. In contrast, an almost complete tumor regression was observed in all mice treated with the two agents in combination. This determined a prolonged life span of the mice that was significantly different as compared with controls (P < 0.001), to MAb C225-treated group (P < 0.001), or to the topotecan-treated group (P < 0.001). All mice of the topotecan plus MAb C225 group were the only animals alive 14 weeks after tumor cell injection. Furthermore, 20% of mice in this group were still alive after 19 weeks. The combined treatment with MAb C225 and topotecan was well tolerated by mice with no signs of acute or delayed toxicity. These results provide a rationale for the evaluation of the anticancer activity of the combination of topoisomerase I inhibitors and anti-EGFR blocking MAbs in clinical trials.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Vigneron, E. Gamelin, and O. Coqueret
The EGFR-STAT3 Oncogenic Pathway Up-regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition
Cancer Res., February 1, 2008; 68(3): 815 - 825.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Harari, G. W. Allen, and J. A. Bonner
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lu, X. Li, K. Liang, R. Luwor, Z. H. Siddik, G. B. Mills, J. Mendelsohn, and Z. Fan
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
Cancer Res., September 1, 2007; 67(17): 8240 - 8247.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Pinto, F Di Fabio, S Siena, S Cascinu, F. Rojas Llimpe, C Ceccarelli, V Mutri, L Giannetta, S Giaquinta, C Funaioli, et al.
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
Ann. Onc., March 1, 2007; 18(3): 510 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. W. Wong, F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, et al.
Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling.
Clin. Cancer Res., October 15, 2006; 12(20): 6186 - 6193.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. A Frieze and J. S McCune
Current Status of Cetuximab for the Treatment of Patients with Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kim, C. N. Prichard, M. N. Younes, Y. D. Yazici, S. A. Jasser, B. N. Bekele, and J. N. Myers
Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., January 15, 2006; 12(2): 600 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Wild, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, F. Luo, A. Camuso, K. McGlinchey, and W. C. Rose
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
Mol. Cancer Ther., January 1, 2006; 5(1): 104 - 113.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Robert, G. Blumenschein, R. S. Herbst, F. V. Fossella, J. Tseng, M. N. Saleh, and M. Needle
Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naive Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9089 - 9096.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tabernero, T. Macarulla, F. J. Ramos, and J. Baselga
Novel targeted therapies in the treatment of gastric and esophageal cancer
Ann. Onc., November 1, 2005; 16(11): 1740 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. G. del Carmen, I. Rizvi, Y. Chang, A. C. E. Moor, E. Oliva, M. Sherwood, B. Pogue, and T. Hasan
Synergism of Epidermal Growth Factor Receptor-Targeted Immunotherapy With Photodynamic Treatment of Ovarian Cancer In Vivo
J Natl Cancer Inst, October 19, 2005; 97(20): 1516 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. Real, A. Benito, J. Cuevas, M. T. Berciano, A. de Juan, P. Coffer, J. Gomez-Roman, M. Lafarga, J. M. Lopez-Vega, and J. L. Fernandez-Luna
Blockade of Epidermal Growth Factor Receptors Chemosensitizes Breast Cancer Cells through Up-Regulation of Bnip3L
Cancer Res., September 15, 2005; 65(18): 8151 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, Z. Chen, M. S. Choe, Y. Lin, S.-Y. Sun, H. S. Wieand, H. J. C. Shin, A. Chen, F. R. Khuri, and D. M. Shin
Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model
Clin. Cancer Res., September 1, 2005; 11(17): 6261 - 6269.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, et al.
Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model
Clin. Cancer Res., August 1, 2005; 11(15): 5558 - 5565.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. T.C. Chan, M.-M. Hsu, B. C. Goh, E. P. Hui, T.-W. Liu, M. J. Millward, R.-L. Hong, J. Whang-Peng, B. B.Y. Ma, K. F. To, et al.
Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
J. Clin. Oncol., May 20, 2005; 23(15): 3568 - 3576.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Yokoi, P. H. Thaker, S. Yazici, R. R. Rebhun, D.-H. Nam, J. He, S.-J. Kim, J. L. Abbruzzese, S. R. Hamilton, and I. J. Fidler
Dual Inhibition of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Phosphorylation by AEE788 Reduces Growth and Metastasis of Human Colon Carcinoma in an Orthotopic Nude Mouse Model
Cancer Res., May 1, 2005; 65(9): 3716 - 3725.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. El-Abaseri, J. Fuhrman, C. Trempus, I. Shendrik, R. W. Tennant, and L. A. Hansen
Chemoprevention of UV Light-Induced Skin Tumorigenesis by Inhibition of the Epidermal Growth Factor Receptor
Cancer Res., May 1, 2005; 65(9): 3958 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
M. R. Raspollini, F. Castiglione, F. Garbini, A. Villanucci, G. Amunni, G. Baroni, V. Boddi, and G. L. Taddei
Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma
International Journal of Surgical Pathology, April 1, 2005; 13(2): 135 - 142.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Venook
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Oncologist, April 1, 2005; 10(4): 250 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Raben, B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Baron, C. Zeng, T. K. Johnson, and P. A. Bunn Jr
The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 795 - 805.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim
Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. Rose and R. Wild
Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts
Clin. Cancer Res., November 1, 2004; 10(21): 7413 - 7417.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. F. Stewart, M. Leggas, J. D. Schuetz, J. C. Panetta, P. J. Cheshire, J. Peterson, N. Daw, J. J. Jenkins III, R. Gilbertson, G. S. Germain, et al.
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
Cancer Res., October 15, 2004; 64(20): 7491 - 7499.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al.
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano
Pharmacological background of EGFR targeting
Ann. Onc., July 1, 2004; 15(7): 1007 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, N. J. Meropol, P. J. Loehrer Sr, M. N. Needle, J. Kopit, and R. J. Mayer
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
J. Clin. Oncol., April 1, 2004; 22(7): 1201 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos
Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound
Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn and J. Baselga
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Grunwald and M. Hidalgo
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone
Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways
Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al.
Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase
Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Bianco, G. Tortora, R. Bianco, R. Caputo, B. M. Veneziani, R. Caputo, V. Damiano, T. Troiani, G. Fontanini, D. Raben, et al.
Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839 (Iressa)
Clin. Cancer Res., October 1, 2002; 8(10): 3250 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn
Targeting the Epidermal Growth Factor Receptor for Cancer Therapy
J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. Baselga
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Oncologist, August 15, 2002; 7(90004): 2 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner
Cancer Res., August 1, 2002; 62(15): 4307 - 4315.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part I
J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Prewett, A. T. Hooper, R. Bassi, L. M. Ellis, H. W. Waksal, and D. J. Hicklin
Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts
Clin. Cancer Res., May 1, 2002; 8(5): 994 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chakravarti, J. S. Loeffler, and N. J. Dyson
Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3-Kinase Signaling
Cancer Res., January 1, 2002; 62(1): 200 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello and G. Tortora
A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor
Clin. Cancer Res., October 1, 2001; 7(10): 2958 - 2970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Moroni, S. Veronese, R. Schiavo, O. Carminati, B. S. Sorensen, M. Gambacorta, and S. Siena
Epidermal Growth Factor Receptor Expression and Activation in Nonseminomatous Germ Cell Tumors
Clin. Cancer Res., September 1, 2001; 7(9): 2770 - 2775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Sausville
Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters : Commentary re: P. Munster et al., Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clin. Cancer Res., August 1, 2001; 7(8): 2155 - 2158.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Tortora, R. Caputo, V. Damiano, R. Bianco, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and F. Ciardiello
Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis
Clin. Cancer Res., August 1, 2001; 7(8): 2537 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Cox, J L Jones, A Andi, D A Waller, and K J O'Byrne
A biological staging model for operable non-small cell lung cancer
Thorax, July 1, 2001; 56(7): 561 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Christ, S. Seiter, S. Matzku, C. Burger, and M. Zöller
Efficacy of Local versus Systemic Application of Antibody-Cytokine Fusion Proteins in Tumor Therapy
Clin. Cancer Res., April 1, 2001; 7(4): 985 - 998.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. D. Ryan and B. A. Chabner
On Receptor Inhibitors and Chemotherapy
Clin. Cancer Res., December 1, 2000; 6(12): 4607 - 4609.
[Full Text]

Home page
 Clin. Cancer Res.Home page
K. Inoue, J. W. Slaton, P. Perrotte, D. W. Davis, C. J. Bruns, D. J. Hicklin, D. J. McConkey, P. Sweeney, R. Radinsky, and C. P. N. Dinney
Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma
Clin. Cancer Res., December 1, 2000; 6(12): 4874 - 4884.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
C. Bianco, R. Bianco, G. Tortora, V. Damiano, P. Guerrieri, P. Montemaggi, J. Mendelsohn, S. De Placido, A. R. Bianco, and F. Ciardiello
Antitumor Activity of Combined Treatment of Human Cancer Cells with Ionizing Radiation and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 plus Type I Protein Kinase A Antisense Oligonucleotide
Clin. Cancer Res., November 1, 2000; 6(11): 4343 - 4350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney
Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel
Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
L. M. Strawn, F. Kabbinavar, D. P. Schwartz, E. Mann, L. K. Shawver, D. J. Slamon, and J. M. Cherrington
Effects of SU101 in Combination with Cytotoxic Agents on the Growth of Subcutaneous Tumor Xenografts
Clin. Cancer Res., July 1, 2000; 6(7): 2931 - 2940.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A. R. Bianco, and G. Tortora
Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor
Clin. Cancer Res., May 1, 2000; 6(5): 2053 - 2063.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. Mendelsohn
Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture
Clin. Cancer Res., March 1, 2000; 6(3): 747 - 753.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.